February 7, 2023
Mochida Pharmaceutical has terminated its codevelopment with Pfizer of the antidepressant MD-120 following the failure of a PIII clinical trial, according to the company’s pipeline update on February 6. The drug maker also jettisoned its program for the pediatric label...read more